Table 3.

Infarct parameters before and 12 weeks after surgery

		Week 12	Week 24	P-value
MI size (% of LV mass)	Placebo	17.3 ± 1.6	18.5 ± 1.2	0.57
	Low-dose MSC	16.3 ± 1.1	12.5 ± 1.0	0.06*
	High-dose MSC	18.2 ± 0.9	14.4 ± 1.0	0.018*†
Infarct volume (cc)	Placebo	8.0 ± 0.9	8.8 ± 1.1	0.59
	Low-dose MSC	7.3 ± 0.5	6.0 ± 1.2	0.37
	High-dose MSC	8.2 ± 0.4	6.6 ± 0.5	0.03†
LV mass (g)	Placebo	45.9 ± 1.4	47.2 ± 3.6	0.75
	Low-dose MSC	45.1 ± 2.1	47.2 ± 4.9	0.71
	High-dose MSC	45.3 ± 0.7	46.1 ± 1.2	0.58
Circumferential extent (% LV circumference)	Placebo	43.8 ± 1.4	45.3 ± 0.8	0.39
	Low-dose MSC	44.7 ± 2.3	36.4 ± 3.3	0.11*
	High-dose MSC	44.3 ± 2.1	31.4 ± 1.3	0.001*†
Infarct thickness (mm)	Placebo	4.0 ± 0.1	3.6 ± 0.2	0.12
	Low-dose MSC	3.3 ± 0.1	4.9 ± 0.5	0.035*†
	High-dose MSC	3.9 ± 0.2	4.9 ± 0.4	0.049*†
Remote thickness (mm)	Placebo	7.1 ± 0.5	7.4 ± 0.5	0.69
	Low-dose MSC	6.9 ± 0.5	7.6 ± 0.5	0.38
	High-dose MSC	6.6 ± 0.5	6.9 ± 0.3	0.62

All values were calculated based on delayed contrast enhanced magnetic resonance imaging.

MI, myocardial infarction; LV, left ventricular.

*P < 0.05 vs. placebo.

^†P < 0.05 week 12 vs. week 24.